|October 22, 2013|
|20:25 EDT||MOLX, MOLX, CMC, CMC, UNF, UNF, PB, PB, ROL, ROL, LCC, LCC, OC, OC, TUP, TUP, NDAQ, NDAQ, OCR, OCR, MDCO, MDCO||Notable companies reporting before tomorrow's open |
Notable companies reporting before tomorrow's market open, with earnings consensus, include Molex (MOLX), consensus 37c; Omnicare (OCR), consensus 90c; Nasdaq OMX (NDAQ), consensus 62c; Tupperware (TUP), consensus $1.03; Owens Corning (OC), consensus 65c; US Airways (LCC), consensus $1.12; Rollins (ROL), consensus 24c; Prosperity Bancshares (PB), consensus 90c; UniFirst (UNF), consensus $1.40; Commercial Metals (CMC), consensus 17c; The Medicines Company (MDCO), consensus 21c.
News For MOLX;OCR;NDAQ;TUP;OC;LCC;ROL;PB;UNF;CMC;MDCO From The Last 14 Days
|October 20, 2014|
|09:48 EDT||MDCO||Brdiger Management reports 5.1% passive stake in The Medicines Co. |
|07:19 EDT||OC||Owens Corning downgraded at Wedbush|
As previously reported, Wedbush downgraded Owens Corning to Neutral from Outperform. The firm downgraded shares based on continued pricing and margin pressures following a competitor dropping prices and a more challenging roofing environment. Price target lowered to $35 from $43.
|07:14 EDT||OC||Owens Corning downgraded to Neutral from Outperform at Wedbush|
|October 17, 2014|
|08:48 EDT||CMC||BofA/Merrill global steel analysts hold analyst/industry conference call|
Subscribe for More Information
|October 14, 2014|
|11:50 EDT||NDAQ||Nasdaq calls JPMorgan earnings release 'human error,' CNBC reports|
Nasdaq (NDAQ) said the early release today of JPMorgan's (JPM) earnings on its Shareholder.com website was an internal "human error," CNBC reports, citing a statement from the exchange. Reference Link
|October 13, 2014|
|07:25 EDT||MDCO||European Association of Cardiothoracic Surgery to hold annual meeting|
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
|October 10, 2014|
|07:14 EDT||MDCO||The Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse|
Subscribe for More Information
|October 9, 2014|
|16:57 EDT||MDCO||The Medicines Co. announces journal publication of SOLO II phase 3 trial|
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.